Difference between revisions of "Thalidomide (Thalomid)"
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
|||
| Line 9: | Line 9: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Light-chain (AL) amyloidosis]] | ||
| + | *[[Multiple myeloma]] | ||
| + | *[[Neuroendocrine tumors]] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 02:02, 21 June 2013
General information
Class/mechanism: Immunomodulatory drug (IMiD); mechanism not fully understood.
Thalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. Thalidomide has been observed to inhibit
angiogenesis in a human umbilical artery explant model in vitro.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Thalidomide (Thalomid) package insert PDF pages 6-7[1]
- Thalidomide (Thalomid) patient drug information (Chemocare)[5]
- Thalidomide (Thalomid) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 1.2 Thalidomide (Thalomid) package insert
- ↑ Thalidomide (Thalomid) package insert (locally hosted backup)
- ↑ Thalomid manufacturer's website
- ↑ S.T.E.P.S. System for Thalidomide Education and Prescribing Safety
- ↑ Thalidomide (Thalomid) patient drug information (Chemocare)
- ↑ Thalidomide (Thalomid) patient drug information (UpToDate)